Lv3
364 积分 2023-12-06 加入
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
1个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
1个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结
Toward personalized treatment approaches for non-small-cell lung cancer
1个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
1个月前
已完结
Non-small-cell lung cancer
1个月前
已完结
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
2个月前
已完结
114P Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial
2个月前
已关闭
Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence
2个月前
已完结
Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group
2个月前
已完结
皖公网安备34019202002308
